OTTAWA: Generic versions of some of the drugs behind the recent surge in demand for diabetes and weight-loss treatments are moving closer to Canadian pharmacy shelves, with several manufacturers targeting launches as early as this summer as Health Canada reviews a growing number of applications. The shift follows the end of Canadian data protection for semaglutide in January, opening the market to copycat filings tied to the active ingredient used in widely known brand-name medicines for blood sugar control and obesity.
Health Canada’s public review records show multiple generic submissions for both semaglutide and liraglutide, two injectable treatments that have become central to the fast-growing market for metabolic disease and weight management. The filings indicate broad industry interest in entering Canada with lower-cost versions after years in which branded products dominated supply and pricing. Public listings identify several drugmakers with semaglutide applications under review, including Sandoz, Apotex, Taro, Aspen and Teva, while liraglutide also has multiple pending submissions.
The regulatory pipeline has drawn attention because semaglutide underpins some of the best-known medicines in the category, including products sold for type 2 diabetes and chronic weight management. Public company statements have pointed to potential Canadian launches during the second half of the year’s first two quarters and into the third quarter, though approval and commercial rollout remain subject to Health Canada review and each company’s final readiness to supply pharmacies once clearance is granted.
Regulatory clock opens market
Aspen has said it expects Canadian registration for an unbranded Ozempic version in late second quarter or the third quarter of 2026, placing a possible launch window between May and September. Sandoz has separately said it expects unbranded Ozempic versions to reach Canada by the end of June 2026, while also indicating its initial focus would be on diabetes patients. Those timelines have helped frame expectations that the first wave of lower-cost semaglutide competition could appear during the summer, rather than later in the year.
Even so, the public record shows an important distinction between copycat semaglutide products expected first for diabetes treatment and a broader rollout of obesity-focused alternatives. Biocon has indicated that a Wegovy-style obesity launch in Canada is likely later, pointing to late 2026 or early 2027, depending on approvals. That means the earliest summer availability discussed publicly is more closely tied to semaglutide products modeled on Ozempic, rather than a full, immediate arrival of weight-loss-labeled versions across the Canadian market.
Pricing and supply in focus
The arrival of generics is being closely watched because of the potential effect on access and pricing in a category that has strained household budgets and drug plans. Sandoz has said discounts of about 60% to 70% to branded list prices are achievable once generic products enter the market. Public health and pharmacy stakeholders have also been monitoring supply conditions, as branded weight-loss and diabetes treatments have faced periods of intense demand in several countries, turning generic entry into a broader issue of affordability and availability.
Health Canada has also approved Novo Nordisk’s rebranded semaglutide products PLOSBRIO and POVIZTRA, but public database entries have listed them as approved rather than marketed. That means the main change expected this summer is not a broad, fully established generic market already on shelves, but a transition period in which regulators are still reviewing applications and manufacturers are preparing for entry once approvals are secured. For Canadian patients and pharmacies, the next major development will be when those pending semaglutide products move from review to sale. – By Content Syndication Services.